BIO Stock Jumps As Elliott Activist Stake Meets Bullish RBC Call

Bio-Rad Laboratories Inc. stocks have been trading up by 13.85 percent following upbeat sentiment around its latest earnings performance.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading BIO

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Elliott Investment Management has built a significant stake in Bio-Rad Laboratories and plans to press for actions to improve the company’s underperforming share price.
RBC Capital resumed coverage of BIO with an Outperform rating and a $320 price target, expecting current product-specific sales headwinds to fade and forecasting a 2027 sales recovery with stronger margins.
Q1 revenue of $592.1M slightly topped expectations and grew 1.1% year over year, but adjusted EPS of $1.89 missed consensus and fell from $2.54 a year earlier.
Management emphasized strong operating and free cash flow in Q1 and bought back shares, signaling confidence in Bio-Rad’s long-term business durability.
The company will present at RBC and Jefferies global healthcare conferences, highlighting Bio-Rad’s life science and diagnostics positioning and its projected $2.6B of 2025 revenue.

Live Update At 16:03:48 EDT: On Monday, May 18, 2026 Bio-Rad Laboratories Inc. stock [NYSE: BIO] is trending up by 13.85%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BIO is starting to trade like a turnaround story with a catalyst. On the tape, Bio-Rad Laboratories just posted Q1 revenue of $592.1M, a touch ahead of the roughly $589.9M Wall Street expected and up 1.1% year over year. That shows demand is holding up even in a tough macro backdrop. The problem is earnings power. Adjusted EPS fell to $1.89 from $2.54 a year ago and missed the $1.97 estimate, a clear sign margins are under pressure.

Despite that, the balance sheet and cash flow picture look strong. Bio-Rad Laboratories generated $108.1M in operating cash flow and $78.1M in free cash flow in the quarter, while ending with about $509M in cash. Debt looks manageable with total debt-to-equity around 0.19 and a healthy current ratio of 5.6, so liquidity risk is low.

On valuation, BIO trades at a price-to-sales of roughly 2.6 and around book value, with a P/E near 40 that’s skewed by noisy GAAP earnings. For traders, this mix — solid cash, pressured EPS, and modest revenue growth — sets up a scenario where any margin improvement can trigger fast re-ratings.

More Breaking News

Technically, BIO is bouncing. After sliding from the high $280s to the mid-$240s earlier in May, Bio-Rad Laboratories has ripped back toward $282, reclaiming key recent resistance and showing expanding intraday ranges that short-term traders like to see.

Why Traders Are Watching BIO Now

BIO has moved from a sleepy life-science name to a headline stock because of who just showed up on the cap table. Elliott Investment Management disclosed a significant stake in Bio-Rad Laboratories and made it clear it plans to push for changes to lift the lagging share price. When a high-profile activist like Elliott steps in, traders pay attention. It usually means pressure on management around strategy, costs, or capital allocation — and historically, that often precedes sharp moves.

Layer that on top of fresh Wall Street support. RBC Capital Markets resumed coverage of Bio-Rad Laboratories with an Outperform rating and a $320 price target. RBC is basically telling the market that current headwinds are more company-specific than structural, and that these issues should ease. The firm expects sales growth to recover in 2027 and highlights new management’s goal to push EBIT margins from 11% in 2026 to the mid-teens through restructuring. That’s a big potential earnings swing if Bio-Rad can execute.

At the same time, BIO is operating inside a favorable macro lane. Industry research projects the global life science instrumentation market will climb from $63.4B in 2025 to $92.5B by 2031, a 6.5% compound annual growth rate. As a major player in life science tools and clinical diagnostics, Bio-Rad Laboratories stands to benefit if it can keep share and sharpen its margin profile.

Short term, traders also have catalysts on the calendar. Bio-Rad Laboratories plans fireside chats and one-on-ones at upcoming RBC and Jefferies global healthcare conferences. With Elliott now involved and RBC pounding the table, those events become potential headline machines. Any hint of a sharper restructuring plan, capital-return tweak, or updated 2025–2027 targets could swing BIO’s tape quickly.

Conclusion

BIO now sits at the intersection of activist pressure, improving sentiment, and still-mixed fundamentals — exactly the kind of tension active traders look for. On one side, Bio-Rad Laboratories delivered “good enough” Q1 numbers: slight revenue beat, 1.1% growth, strong free cash flow, and ongoing buybacks that signal management believes the long-term story. On the other side, falling EPS and prior underperformance explain why Elliott found an opening.

From a structure standpoint, Bio-Rad Laboratories has a clean balance sheet, ample liquidity, and exposure to an industry expected to grow steadily through 2031. RBC’s $320 target and margin expansion thesis give a clear road map for what a successful turnaround might look like. If new management can move EBIT margins from 11% into the mid-teens, the earnings math behind BIO changes fast, which is exactly what momentum traders hunt.

But nothing is guaranteed. Activist campaigns sometimes drag on, restructuring can be messy, and Q1 showed that profits are not yet stabilized. That’s why discipline matters. As Tim Sykes likes to remind traders, “the market doesn’t care about your opinion, only your preparation — study the pattern, size your risk, and cut losses quickly.” As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.”. For anyone tracking BIO, that means watching the charts around support and resistance, listening closely to the coming conference chatter, and treating every move as a trading setup, not a promise.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!